Locations
Oxford, UK · London, UK · England, UK · Mile End, London, UK · Kingston Vale, London SW15, UK
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2021
Amber Therapeutics is pioneering the first adaptive neuromodulation therapy for women suffering from mixed urinary incontinence. Their flagship product, the Picostim TM System, is a fully implantable device that targets the pudendal nerve, providing personalized treatment by dynamically adapting to the patient's physiological responses. With a significant market need—40 million women in the US affected by urinary incontinence and only 16 million receiving therapy—Amber's innovative approach addresses both urge and stress incontinence, setting it apart from existing therapies. The company has demonstrated promising results in its AURA-2 study, showcasing safety and efficacy, and aims to transform the quality of life for millions of women globally.
Something looks off?